02.01.23 -- Cell & Gene Best Of January

Plasmid release specifications are critical to the manufacture of many cell and gene therapy products, but current guidance defining expectations for the release of plasmids as a starting material is limited. In this article, BioPhorum summarizes key industry feedback, best practices, and member discussions on the topic.

Once a month, my Life Science Connect editorial colleagues and I meet to discuss the most pressing topics in our respective coverage areas to learn from each other and to address any overlaps (hint: there are always many overlapping issues). Fresh off our most recent meeting, I thought I’d share with you what we covered and what are just some of the topics and trends Cell & Gene will continue to cover into next year.

Leveraging human genetics data early in the drug discovery process to inform target prioritization is a powerful approach to mitigate risk and increase the likelihood of advancing safe therapies that make a transformative impact in patients’ lives.

Discover how digital holographic microscopy (DHM) can be implemented for online monitoring of Sf9 concentration and viability and for monitoring product titer (AAV) or culture progression in lytic systems.

Discuss ways to leverage genetic laboratories to help increase success rates and drive efficient and effective rare disease patient recruitment.

When scientists spend long hours in the lab, their environment influences productivity, output, and overall job satisfaction. Learn how to design a space that attracts and inspires top talent.